Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial.

Auteurs : Oakman C, Francis PA, Crown J, Quinaux E, Buyse M, de Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Jakesz R, Thürlimann B, Gutiérrez J, Harvey V, Punzalan L, Dell orto P, Larsimont D, Steinberg I, Gelber Rd, Piccart-Gebhart M, Viale G, Di Leo A
Jaar : 2013
Journal : Ann Oncol
Volume : 24(5)
Pagina's : 1203-11